-  INCLUSION CRITERIA:

               1. Unresectable thyroid cancer expressing TG as assessed by one of the following
                  methods: RT-PCR on tumor tissue, or by immunohistochemistry of resected tissue.

               2. Recurrent/metastatic radioiodine refractory disease that has progressed within
                  the past 6 months with at least 1 lesion increasing by 0.5cm in diameter or with
                  increasing bone metastases.

               3. Confirmation of diagnosis of thyroid cancer by the Laboratory of Pathology of the
                  NCI.

               4. PET avid disease with SUV >5.

               5. Patients must have previously received standard systemic therapy for advanced
                  thyroid cancer (to include radioactive iodine for iodine-avid tumors and surgery
                  (if indicated)) and have been either non-responders (progressive disease) or have
                  recurred.

               6. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and
                  asymptomatic are eligible. Lesions that have been treated with stereotactic
                  radiosurgery must be clinically stable for 1 month after treatment for the
                  patient to be eligible.

               7. Greater than or equal to 18 years of age and less than or equal to 70 years of
                  age.

               8. Willing to sign a durable power of attorney

               9. Able to understand and sign the Informed Consent Document

              10. Clinical performance status of ECOG 0 or 1

              11. Life expectancy of greater than three months

              12. Patients must be HLA-A*0201 positive

              13. Patients of both genders must be willing to practice birth control from the time
                  of enrollment on this study and for up to four months after treatment.

              14. Serology:

          -  Seronegative for HIV antibody. (The experimental treatment being evaluated in this
             protocol depends on an intact immune system. Patients who are HIV seropositive can
             have decreased immune-competence and thus be less responsive to the experimental
             treatment and more susceptible to its toxicities.)

          -  Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If
             hepatitis C antibody test is positive, then patient must be tested for the presence of
             antigen by RT-PCR and be HCV RNA negative.

             o. Women of child-bearing potential must have a negative pregnancy test because of the
             potentially dangerous effects of the treatment on the fetus.

             p. Hematology

          -  Absolute neutrophil count greater than 1000/mm3 without the support of filgrastim

          -  WBC less than or equal to 3000/mm3

          -  Platelet count greater than or equal to 100,000/mm3

          -  Hemoglobin greater than 8.0 g/dl

             q. Chemistry:

          -  Serum ALT/AST less than or equal to to 2.5 times the upper limit of normal

          -  Serum creatinine less than or equal to to 1.6 mg/dl

          -  Total bilirubin less than or equal to to 1.5 mg/dl, except in patients with Gilbert s
             Syndrome who must have a total bilirubin less than 3.0 mg/dl.

             r. More than four weeks must have elapsed since any prior systemic therapy at the time
             the patient receives the preparative regimen, and patients toxicities must have
             recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).

        Note: Patients may have undergone minor surgical procedures within the past 3 weeks, as
        long as all toxicities have recovered to grade 1 or less.

        EXCLUSION CRITERIA:

          1. Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the treatment on the fetus or infant.

          2. Any form of primary immunodeficiency (such as Severe Combined

             Immunodeficiency Disease).

          3. Active systemic infections (e.g. : requiring anti-infective treatment), coagulation
             disorders or other major medical illnesses of the cardiovascular, respiratory or
             immune system, myocardial infarction, cardiac arrhythmias, obstructive or restrictive
             pulmonary disease.

          4. Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who have decreased immune
             competence may be less responsive to the experimental treatment and more susceptible
             to its toxicities).

          5. Concurrent systemic steroid therapy.

          6. History of severe immediate hypersensitivity reaction to cyclophosphamide or
             fludarabine.

          7. History of coronary revascularization or ischemic symptoms

          8. Documented LVEF of less than or equal to 45%. Testing is required in patients with:

               -  Clinically significant atrial and/or ventricular arrhythmias including but not
                  limited to: atrial fibrillation, ventricular tachycardia, second or third degree
                  heart block

               -  Age greater than or equal to 60 years old